Compare Stocks: HEC, BTTX, UPHL, and HELP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BTTX Better Therapeutics	$0.00	$0.00	$0.00 ▼ $0.00	$4K	0.9	9,648 shs	255 shs
HEC Hudson Executive Investment	$5.16	$8.58	$7.82 ▼ $12.45	$213.62M	N/A	1.42 million shs	2.17 million shs
HELP Cybin	$8.68 -3.9%	$11.70	$3.76 ▼ $15.15	$720.66M	0.64	1.57 million shs	1.25 million shs
UPHL UpHealth	$0.00	$0.00	$0.00 ▼ $0.10	$4K	0.26	5,338 shs	100,247 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BTTX Better Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
HEC Hudson Executive Investment	0.00%	0.00%	0.00%	0.00%	+57.32%
HELP Cybin	-3.88%	-20.44%	-23.99%	-21.80%	+867,999,900.00%
UPHL UpHealth	0.00%	-33.33%	+100.00%	+100.00%	0.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BTTX Better Therapeutics	$0.00	$0.00	$0.00 ▼ $0.00	$4K	0.9	9,648 shs	255 shs
HEC Hudson Executive Investment	$5.16	$8.58	$7.82 ▼ $12.45	$213.62M	N/A	1.42 million shs	2.17 million shs
HELP Cybin	$8.68 -3.9%	$11.70	$3.76 ▼ $15.15	$720.66M	0.64	1.57 million shs	1.25 million shs
UPHL UpHealth	$0.00	$0.00	$0.00 ▼ $0.10	$4K	0.26	5,338 shs	100,247 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BTTX Better Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
HEC Hudson Executive Investment	0.00%	0.00%	0.00%	0.00%	+57.32%
HELP Cybin	-3.88%	-20.44%	-23.99%	-21.80%	+867,999,900.00%
UPHL UpHealth	0.00%	-33.33%	+100.00%	+100.00%	0.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BTTX Better Therapeutics	0.00	N/A	N/A	N/A
HEC Hudson Executive Investment	0.00	N/A	N/A	N/A
HELP Cybin	3.00	Buy	$47.33	445.31% Upside
UPHL UpHealth	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest HEC, BTTX, UPHL, and HELP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/22/2026	HELP Cybin	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$16.00 ➝ $22.00
9/18/2026	HELP Cybin	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$35.00
8/20/2026	HELP Cybin	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$8.00 ➝ $62.00

(Data available from 11/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BTTX Better Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
HEC Hudson Executive Investment	N/A	N/A	N/A	N/A	$0.12 per share	N/A
HELP Cybin	N/A	N/A	N/A	N/A	$4.49 per share	N/A
UPHL UpHealth	$130M	0.00	N/A	N/A	$3.10 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BTTX Better Therapeutics	-$39.76M	-$0.15	N/A	N/A	N/A	N/A	N/A	N/A	11/12/2026 (Estimated)
HEC Hudson Executive Investment	-$27.24M	N/A	N/A	N/A	N/A	N/A	-337.48%	-4.06%	N/A
HELP Cybin	-$148M	-$3.02	N/A	N/A	N/A	N/A	-71.78%	-64.81%	N/A
UPHL UpHealth	-$56.42M	$2.38	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest HEC, BTTX, UPHL, and HELP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
11/12/2026	N/A	BTTX Better Therapeutics	-$0.21	N/A	N/A	N/A	$6.58 million	N/A
8/14/2026	Q1 2027	HELP Cybin	-$0.80	-$0.91	-$0.11	-$0.91	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BTTX Better Therapeutics	N/A	N/A	N/A	N/A	N/A
HEC Hudson Executive Investment	N/A	N/A	N/A	N/A	N/A
HELP Cybin	N/A	N/A	N/A	N/A	N/A
UPHL UpHealth	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BTTX Better Therapeutics	N/A	N/A	N/A
HEC Hudson Executive Investment	N/A	0.33	0.33
HELP Cybin	N/A	10.97	10.97
UPHL UpHealth	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BTTX Better Therapeutics	34.00%
HEC Hudson Executive Investment	73.41%
HELP Cybin	17.94%
UPHL UpHealth	56.10%

Insider Ownership

Company	Insider Ownership
BTTX Better Therapeutics	51.40%
HEC Hudson Executive Investment	N/A
HELP Cybin	15.00%
UPHL UpHealth	34.24%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BTTX Better Therapeutics	54	40.58 million	24.23 million	No Data
HEC Hudson Executive Investment	N/A	41.40 million	N/A	Not Optionable
HELP Cybin	100	79.81 million	67.84 million	Optionable
UPHL UpHealth	374	18.93 million	12.45 million	No Data

HEC, BTTX, UPHL, and HELP Headlines

Recent News About These Companies

UpHealth Delays Latest Quarterly SEC Filing

August 14, 2026 | tipranks.com

UpHealth Delays Latest Quarterly SEC Filing

May 15, 2026 | tipranks.com

UpHealth Inc.

May 14, 2026 | marketwatch.com

UpHealth Delays Q2 2025 10-Q Filing

August 14, 2025 | msn.com

UpHealth, Inc. (UPHL) Latest Stock News & Headlines - Yahoo Finance

April 23, 2025 | finance.yahoo.com

Lemon Dump Cake Recipe

September 9, 2024 | msn.com

DJUSIV Dow Jones US Business Support Services Index

July 27, 2024 | seekingalpha.com

UpHealth Inc Ordinary Shares UPHL

July 19, 2024 | morningstar.comM

UpHealth Holdings, Inc. Wins Ruling in Calcutta High Court, Mandating All Glocal Healthcare Respondents Submit Affidavits of Assets

May 24, 2024 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

HEC, BTTX, UPHL, and HELP Company Descriptions

Better Therapeutics NASDAQ:BTTX

$0.0001 0.00 (0.00%)

As of 11/3/2026 09:46 AM Eastern

Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.

Hudson Executive Investment NASDAQ:HEC

Hudson Executive Investment Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.

Cybin NASDAQ:HELP

$8.68 -0.35 (-3.88%)

Closing price 11/4/2026 04:00 PM Eastern

Extended Trading

$8.75 +0.07 (+0.81%)

As of 04:00 AM Eastern

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a discovery-phase phenethylamine derivative to treat neuroinflammation and psychiatric conditions. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.

UpHealth NYSE:UPHL

$0.0002 0.00 (0.00%)

As of 11/3/2026 12:54 PM Eastern

UpHealth, Inc. provides behavioral health solutions through the utilization of evidence-based treatments and services in the Americas. The company offers mental health and substance use disorder treatment services directly to consumers. It also provides detoxification, residential, partial hospitalization program, intensive outpatient program, outpatient services, and non-clinical recovery residence and supporting housing services. UpHealth, Inc. is headquartered in Delray Beach, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HEC, BTTX, UPHL, and HELP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HEC, BTTX, UPHL, and HELP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HEC, BTTX, UPHL, and HELP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HEC, BTTX, UPHL, and HELP Company Descriptions

Better Therapeutics NASDAQ:BTTX

Hudson Executive Investment NASDAQ:HEC

Cybin NASDAQ:HELP

UpHealth NYSE:UPHL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HEC, BTTX, UPHL, and HELP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HEC, BTTX, UPHL, and HELP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HEC, BTTX, UPHL, and HELP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HEC, BTTX, UPHL, and HELP Company Descriptions

Better Therapeutics NASDAQ:BTTX

Hudson Executive Investment NASDAQ:HEC

Cybin NASDAQ:HELP

UpHealth NYSE:UPHL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools